# Generation Bio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/generation-bio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.generationbio.com
- Total disclosed funding: $237M
- Latest round: Series C (Jan 9, 2020)
- Investors on record: 10

## About

Generation Bio Co. specializes in developing innovative therapeutics for T cell-driven autoimmune diseases, focusing on proprietary cell-targeted lipid nanoparticles technology for targeted gene modulation.Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, US. The company focuses on developing therapeutics that utilize small interfering RNA to address autoimmune diseases. The firm was co-founded by Andy Scharenberg, Mark A, and Phillip Samayoa, with Geoffrey McDonough serving as CEO. The company has raised a total of USD 196.00 mn through funding rounds, including a PRIVATE PLACEMENT in January 2021.Generation Bio specializes in developing innovative therapeutics for T cell-driven autoimmune diseases, primarily leveraging their proprietary cell-targeted lipid nanoparticles (ctLNP) technology. This technology allows for selective modulation of T cell function using small interfering RNA (siRNA), aimed at reducing autoreactive T cells responsible for conditions like multiple sclerosis and rheumatoid arthritis. Their products target healthcare providers in North America and Europe, focusing on unmet medical needs in autoimmune disease treatment.In 2023, Generation Bio reported a revenue of USD 5.90 mn and an EBITDA of USD -142.64 mn, reflecting the company's investment in research and development for their therapeutic products.Generation Bio plans to utilize recent funding of USD 196.00 mn from their January 2021 PRIVATE PLACEMENT to enhance their drug development pipeline. The firm aims to launch new products targeting T cell-driven autoimmune diseases and expand their reach into North American and European markets, aligning with their strategic focus on advancing ctLNP technology for better treatment options. Recent capital will support these initiatives as they continue to grow their innovative therapeutics portfolio.

## Funding rounds

- Series C, Jan 9, 2020, $111M — Atlas Venture, T Rowe Price, Invus [DUP], Wellington Management, Fidelity Investments, Leerink Partners, Foresite Capital, Casdin Capital, Deerfield Management, Farallon Capital Management
- Series B, Feb 27, 2018, $100M — Invus [DUP], Fidelity Investments, Leerink Partners, Foresite Capital, Casdin Capital, Deerfield Management
- Series A, Jan 4, 2018, $25M — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series C
- Invus [DUP] — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Leerink Partners — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C